ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/PSMA
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/PSMA
20
trial(s) found.
NCT07611110
Advanced
Phase 3
Recruiting
A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (
VECTRA-01
)
radioligand,PSMA-targeting
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT07590934
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer (
PROSPECTOR
)
AZD2265
Docetaxel
PARP1-selective inhibitor
PARP inhibitor
Palacaparib
cancer therapy
cancer therapy,PARP-targeting
cancer therapy,PARP1-selective-targeting
cancer therapy,PSMA-targeting
cytotoxic chemotherapy
radioligand,PSMA-targeting
radionuclide therapy
radionuclide therapy,PSMA-targeting
radiopharmaceutics
taxane
+ cancer therapy,PSMA-targeting
Prostate cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07226986
Radonc
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) (
CAMO959A12103
)
DNA-dependent protein kinase inhibitor
radioconjugate,PSMA-targeting
Castrate-resistant prostate cancer
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07090369
Radonc
Phase 1
Not yet recruiting
Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (
LumOnate
)
PARP1/2 inhibitor
anti-PD-1 monoclonal antibody
radioconjugate,PSMA-targeting
Castrate-resistant prostate cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06879041
Advanced
Phase 1
Recruiting
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer (
D7580C00001
)
radioligand,PSMA-targeting
Castrate-resistant prostate cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06855277
Radonc
Phase 3
Recruiting
A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (
AcTFirst
)
radioligand,PSMA-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06780670
Advanced
Phase 2 / Phase 3
Recruiting
PSMAcTION
: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
radioligand,PSMA-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06520345
Radonc
Phase 3
Recruiting
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment (
177Lu-TLX591-203
)
radioconjugate,PSMA-targeting
Castrate-resistant prostate cancer
Prostate cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3051 - Melbourne - Australian Prostate Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
WA
6150 - Murdoch - GenesisCare Murdoch
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06492122
Radonc
Phase 1
Recruiting
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC. (
ProTACT
)
anit-PSMA radionucleotide-drug conjugate,PSMA-targeting
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - St John of God Murdoch Hospital
NCT06095089
Advanced
Phase 1
Recruiting
A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer (
CR109330
)
bispecific T-cell engager,KLK2-targeting
+ cancer therapy,PSMA-targeting
Prostate cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05939414
Radonc
Phase 3
Recruiting
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC) (
PSMA-DC
)
radioconjugate,PSMA-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05818683
Advanced
Phase 1
Recruiting
A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer (
CR109321
)
bispecific T-cell engager,KLK2-targeting
+ cancer therapy,PSMA-targeting
Castrate-resistant prostate cancer
Castrate-sensitive prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT05720130
Radonc
Phase 1 / Phase 2
Recruiting
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). (
PSMA-AC-01
)
radioligand,PSMA-targeting
Castrate-resistant prostate cancer
Castrate-sensitive prostate cancer
Prostate cancer
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
NCT05519449
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (
PSMA-007-001
)
PSMA-tumor-activated T-cell engager
Castrate-resistant prostate cancer
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
ACTRN12625000971437
Radonc
Phase 2
Recruiting
Dose Optimisation and PSMA Receptor intensification with 177Lu-PSMA Therapy in Patients Diagnosed with Metastatic Castrate Resistant Prostate Cancer : A Randomised Phase II trial:
OPTIMAL-PSMA
radioconjugate,PSMA-targeting
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
ACTRN12623001072606
Radonc
Phase 1
Recruiting
A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC) (
LuCape
)
fluoropyrimidine
radioconjugate,PSMA-targeting
Castrate-resistant prostate cancer
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000216617
Radonc
Phase 1
Not yet recruiting
A pilot, feasibility study of 177Lu-DOTA-Rosopatamab (TLX591) therapy in castrate resistant prostate adenocarcinoma patients showing progression on radioligand therapy using PSMA small molecule ligands (
RESCUE
)
radioligand,PSMA-targeting
Prostate cancer
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12623000073606
Radonc
Phase 0
Not yet recruiting
A Single-Arm, Open-Label, Prospective, Phase 0 Trial Evaluating the Safety and Efficacy of Salvage 177Lu-PSMA-I&T in Prostate Specific Antigen (PSA) Biochemical Failure After Radical Prostatectomy for High-Risk Prostate Cancer (
SLAP-trial
)
radioconjugate,PSMA-targeting
Prostate cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
ACTRN12622001378718
Radonc
Phase 1 / Phase 2
Recruiting
Phase I/IIa Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma (TheraPb – Phase I/II) (
TheraPb-phase-I-II
)
radioligand,PSMA-targeting
Prostate cancer
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12618001667202
Radonc
Phase 3
Not yet recruiting
A Randomised Trial of External Beam Radiation Therapy (EBRT) Alone versus EBRT in Combination with 177Lu-PSMA Theranostic in Patients with Biochemically Recurrent Prostate Cancer (to determine the proportion of participants in each group with a 50% decline in PSA through to the end of the trial) - a phase 3 study (
TARGET
)
radioconjugate,PSMA-targeting
radiotherapy
Prostate cancer
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (16)
Not yet recruiting (4)
Recruitment Country and State
NSW (10)
VIC (9)
QLD (7)
WA (6)
SA (5)
NZ (2)
Phase
Phase 0 (1)
Phase 1 (8)
Phase 1 / Phase 2 (4)
Phase 2 (1)
Phase 2 / Phase 3 (1)
Phase 3 (5)
Trial Type
Radonc (13)
Advanced (7)
Cancer Therapy Class
PSMA
100%
AR
35%
androgen axis
35%
CYP17A1
25%
PARP
10%
PD-1
10%
PD-1/PD-L1
10%
KLK2
10%
PARP1-selective
5%
DNA-dependent protein kinase
5%
Facility
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
3004 - Melbourne, Southbank - Alfred Health (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
NA
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2109 - North Ryde - Macquarie University Hospital (2)
3002 - East Melbourne - Epworth Freemasons (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3051 - Melbourne - Australian Prostate Centre (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
6150 - Murdoch - GenesisCare Murdoch (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
6150 - Murdoch - St John of God Murdoch Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
4215 - Southport - Gold Coast University Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
6009 - Nedlands - Linear Clinical Research (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
Cancer Type
Cancer
Male genital cancers
Prostate cancer
Solid tumour
Urogenital cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Castrate-sensitive prostate cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy